EA012309B1 - Применение макролидов для лечения флегмоны кишечника - Google Patents
Применение макролидов для лечения флегмоны кишечника Download PDFInfo
- Publication number
- EA012309B1 EA012309B1 EA200702036A EA200702036A EA012309B1 EA 012309 B1 EA012309 B1 EA 012309B1 EA 200702036 A EA200702036 A EA 200702036A EA 200702036 A EA200702036 A EA 200702036A EA 012309 B1 EA012309 B1 EA 012309B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- formula
- inflammatory bowel
- pharmaceutically acceptable
- disease
- bowel disease
- Prior art date
Links
- 239000003120 macrolide antibiotic agent Substances 0.000 title description 13
- 206010061218 Inflammation Diseases 0.000 title description 6
- 230000004054 inflammatory process Effects 0.000 title description 6
- 230000000968 intestinal effect Effects 0.000 title description 5
- 229940041033 macrolides Drugs 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 23
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 10
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 230000002265 prevention Effects 0.000 claims abstract description 5
- -1 1-oxoethyl Chemical group 0.000 claims description 9
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 7
- 208000011231 Crohn disease Diseases 0.000 claims description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 210000001072 colon Anatomy 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 206010009887 colitis Diseases 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- OVOJUAKDTOOXRF-UHFFFAOYSA-N 2,4-dinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O OVOJUAKDTOOXRF-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 150000003873 salicylate salts Chemical class 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010007882 Cellulitis Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- GWGBNENHEGYJSN-UHFFFAOYSA-N 2,4-dinitrobenzenesulfonic acid;hydrate Chemical compound O.OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O GWGBNENHEGYJSN-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000007433 macroscopic evaluation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05102244 | 2005-03-21 | ||
| PCT/EP2006/060709 WO2006100195A1 (en) | 2005-03-21 | 2006-03-14 | Use of macrolides for treating intestinal inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200702036A1 EA200702036A1 (ru) | 2008-02-28 |
| EA012309B1 true EA012309B1 (ru) | 2009-08-28 |
Family
ID=36649815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200702036A EA012309B1 (ru) | 2005-03-21 | 2006-03-14 | Применение макролидов для лечения флегмоны кишечника |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080249034A1 (enExample) |
| EP (1) | EP1868619A1 (enExample) |
| JP (1) | JP2008533186A (enExample) |
| CN (1) | CN101212980A (enExample) |
| AU (1) | AU2006226381B2 (enExample) |
| BR (1) | BRPI0614009A2 (enExample) |
| CA (1) | CA2601640C (enExample) |
| EA (1) | EA012309B1 (enExample) |
| IT (1) | ITMI20060460A1 (enExample) |
| MX (1) | MX2007011544A (enExample) |
| WO (1) | WO2006100195A1 (enExample) |
| ZA (1) | ZA200708423B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1907406T3 (da) * | 2005-07-06 | 2010-08-09 | Zambon Spa | Krystallinske former af macrolidforbindelser med betændelseshæmmende effekt |
| WO2008065636A2 (en) * | 2006-12-01 | 2008-06-05 | University College York - National University Of Ireland, Cork | Treatment of disease by modulating cf5 protein |
| KR20240004268A (ko) * | 2021-02-26 | 2024-01-11 | 팬더릭스 인코포레이티드 | 안정화된 초유 조성물 |
| CN113209084A (zh) * | 2021-05-18 | 2021-08-06 | 南开大学 | 化合物cp0119在制备用于治疗炎性肠病的药物中的应用 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2089219C1 (ru) * | 1994-02-22 | 1997-09-10 | Александра Леонидовна Бурмистрова | Способ лечения неспецифического язвенного колита |
| US5712253A (en) * | 1996-06-18 | 1998-01-27 | Abbott Laboratories | Macrocyclic 13-membered ring derivatives of erythromycins A and B |
| WO2000042055A2 (en) * | 1999-01-15 | 2000-07-20 | Zambon Group S.P.A. | Macrolides with anti-inflammatory activity |
| RU2000100938A (ru) * | 1997-07-10 | 2001-11-10 | Теракос, Инк. | Лечение воспалительных заболеваний кишечника и мочевого пузыря |
| US20020035075A1 (en) * | 1997-04-01 | 2002-03-21 | Borody Thomas Julius | Methods and compositions for treating inflammatory bowel disease |
| WO2004013153A2 (en) * | 2002-08-01 | 2004-02-12 | Zambon Group S.P.A. | Macrolide compounds endowed with antiinflammatory activity |
| US20040198677A1 (en) * | 2001-01-09 | 2004-10-07 | Mlanden Mercep | Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy |
| WO2005075494A1 (en) * | 2004-01-29 | 2005-08-18 | Zambon Group S.P.A. | Macrolides with antiinflammatory activity |
-
2005
- 2005-03-14 US US11/908,550 patent/US20080249034A1/en not_active Abandoned
-
2006
- 2006-03-14 EP EP06725052A patent/EP1868619A1/en not_active Withdrawn
- 2006-03-14 WO PCT/EP2006/060709 patent/WO2006100195A1/en not_active Ceased
- 2006-03-14 AU AU2006226381A patent/AU2006226381B2/en not_active Ceased
- 2006-03-14 CA CA2601640A patent/CA2601640C/en not_active Expired - Fee Related
- 2006-03-14 CN CNA2006800126183A patent/CN101212980A/zh active Pending
- 2006-03-14 MX MX2007011544A patent/MX2007011544A/es not_active Application Discontinuation
- 2006-03-14 EA EA200702036A patent/EA012309B1/ru not_active IP Right Cessation
- 2006-03-14 JP JP2008502380A patent/JP2008533186A/ja active Pending
- 2006-03-14 BR BRPI0614009-2A patent/BRPI0614009A2/pt not_active IP Right Cessation
- 2006-03-15 IT IT000460A patent/ITMI20060460A1/it unknown
-
2007
- 2007-10-02 ZA ZA200708423A patent/ZA200708423B/xx unknown
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2089219C1 (ru) * | 1994-02-22 | 1997-09-10 | Александра Леонидовна Бурмистрова | Способ лечения неспецифического язвенного колита |
| US5712253A (en) * | 1996-06-18 | 1998-01-27 | Abbott Laboratories | Macrocyclic 13-membered ring derivatives of erythromycins A and B |
| US20020035075A1 (en) * | 1997-04-01 | 2002-03-21 | Borody Thomas Julius | Methods and compositions for treating inflammatory bowel disease |
| RU2000100938A (ru) * | 1997-07-10 | 2001-11-10 | Теракос, Инк. | Лечение воспалительных заболеваний кишечника и мочевого пузыря |
| WO2000042055A2 (en) * | 1999-01-15 | 2000-07-20 | Zambon Group S.P.A. | Macrolides with anti-inflammatory activity |
| US20040198677A1 (en) * | 2001-01-09 | 2004-10-07 | Mlanden Mercep | Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy |
| WO2004013153A2 (en) * | 2002-08-01 | 2004-02-12 | Zambon Group S.P.A. | Macrolide compounds endowed with antiinflammatory activity |
| WO2005075494A1 (en) * | 2004-01-29 | 2005-08-18 | Zambon Group S.P.A. | Macrolides with antiinflammatory activity |
Non-Patent Citations (3)
| Title |
|---|
| "The Merck Manual" 1999, MERCK RESEARCH LABORATORIES, USA, XP002391025 pages 302-312 * |
| L.V. SABANOV i dr. Bolezn' krona: osobennosti proyavleniya, diagnostiki i lecheniya. Lekarstvennyy vestnik, 2002, Ôäû 1, str. 10-15 * |
| V.V. NEPOGODA i dr. Lechenie nespetsificheskogo yazvennogo kolita. Lekarstvennyy vestnik, 2002, Ôäû 1, str. 16-20 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200708423B (en) | 2009-03-25 |
| WO2006100195A1 (en) | 2006-09-28 |
| AU2006226381B2 (en) | 2011-09-08 |
| AU2006226381A1 (en) | 2006-09-28 |
| BRPI0614009A2 (pt) | 2011-03-01 |
| CN101212980A (zh) | 2008-07-02 |
| US20080249034A1 (en) | 2008-10-09 |
| MX2007011544A (es) | 2008-03-11 |
| CA2601640A1 (en) | 2006-09-28 |
| CA2601640C (en) | 2013-10-22 |
| ITMI20060460A1 (it) | 2006-09-22 |
| JP2008533186A (ja) | 2008-08-21 |
| EA200702036A1 (ru) | 2008-02-28 |
| EP1868619A1 (en) | 2007-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013258566B2 (en) | Pyrazole derivative and use thereof for medical purposes | |
| JP7783743B2 (ja) | 硫酸コンドロイチン多糖類、その半合成調製方法および使用 | |
| KR940011244B1 (ko) | 신장 질환 치료제 | |
| KR20190124713A (ko) | 염증성 장 질환 및 장 결장염을 치료하는데 사용하기 위한 조성물 | |
| EA012309B1 (ru) | Применение макролидов для лечения флегмоны кишечника | |
| ITRM960396A1 (it) | Uso di alcanoil l-carnitine nel trattamento terapeutico di malattie infiammatorie croniche intestinali. | |
| CN117771232A (zh) | 芹菜素在制备用于治疗炎症药物中的应用 | |
| WO2016121147A1 (ja) | 注腸剤 | |
| WO2024078468A1 (zh) | 二苯乙烯衍生物用于预防和或治疗溃疡的用途 | |
| JP2018108993A (ja) | 注腸剤 | |
| PT2106258E (pt) | Ibuprofeno contra a tosse | |
| WO2023066330A1 (zh) | 依达拉奉在自闭症谱系障碍治疗中的应用 | |
| CN115025076A (zh) | 利多卡因或其药学上可接受的盐在制备用于溃疡性结肠炎灌肠治疗的药物组合物中的用途 | |
| CN105079012B (zh) | 天麻素在制备防治溃疡性结肠炎的药物或食品中的应用 | |
| CN111184706B (zh) | 一种防治胆囊炎的活性药物及其用途 | |
| CN105147661B (zh) | 升麻素在制备防治溃疡性结肠炎的药物或食品中的应用 | |
| TW200404568A (en) | Alleviation of upper gastrointestinal irritation | |
| CN112704727A (zh) | 特利加压素在制备动力性肠梗阻药物中的应用 | |
| WO2023245470A1 (zh) | Mdp类似物在制备用于治疗炎症性肠病的药物中的用途 | |
| CN117298247A (zh) | Mdp类似物在制备用于治疗炎症性肠病的药物中的用途 | |
| CN112826820A (zh) | Nlrp3抑制剂及其应用 | |
| Hagger et al. | A placebo-controlled study to evaluate the effect on colonic transit of R093877 in healthy volunteers | |
| CN118203578A (zh) | 奥赛利定在制备预防或治疗围术期低体温的药物中的应用 | |
| JP2006117569A (ja) | ステロイド依存性あるいはステロイド抵抗性潰瘍性大腸炎治療薬 | |
| Hahn et al. | Effect of endomorphin-1 and endomorphin-2 on the ascending and descending reflex pathway in rat intestine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |